Boardroom Alpha
Start trial
8-K primary document
EXOZ · Current Report (Form 8-K) · Filed July 1, 2026

Exozymes Inc — 8-K exhibit

ex10-3.htm
Exozymes Inc on Boardroom Alpha

 

Exhibit 10.3

 

Modification to Warrant Agent Agreement

Between

eXoZymes Inc. and VStock Transfer LLC

 

This modification agreement dated June 30, 2026, is to that certain Warrant Agent Agreement between eXoZymes and VStock Transfer LLC, dated as of June 5, 2026, for the purpose of adding the securities to the terms of the Warrant Agent Agreement.

 

Capitalized terms used in this modification shall have the same meanings as assigned in the Warrant Agent Agreement.

 

The parties hereto agree that the first whereas clause will be removed in in its place will be inserted the following:

 

“WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated June 5, 2026, by and among the Company and Public Ventures, LLC (d/b/a MDB Capital), as representative of the underwriters (the “Underwriters”) set forth therein and that certain Placement Agent Agreement (“Placement Agent Agreement”) dated June 30, 2026, by and between the Company and Public Ventures, LLC, the Company is engaged in a public offering and public placement of securities of the Company (the “Offering”) of 732,260 shares (the “Shares”) of common stock, par value $0.000001 per share (the “Common Stock”), and 366,130 warrants (the “Warrants”) to purchase up to 366,130 shares of Common Stock (the “Warrant Shares”;”

 

IN WITNESS WHEREOF, this Warrant Agent Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

EXOZYMES INC  
     
By: /S/ Michael Heltzen  
Name: Michael Heltzen  
Title: Chief Executive Officer  

 

VSTOCK TRANSFER LLC  
     
By: /S/ Young D. Kim  
Name: Young D. Kim, Esq  
Title: Compliance Officer   

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer